NB is different from many other cancer types in that its clinical presentation can be extremely heterogeneous: While high risk NB (International Neuroblastoma Staging System (INSS)-stage 4) is an aggressive disease with an overall 5-year survival of only about 30% in MYCN-amplified patients, stage 4s NB can spontaneously regress and often does not even require treatment (5-year survival rates of more than 90%) (11). The gene discussed is MYCN; the disease is neuroblastoma.